Functional screening for compounds that promote remyelination represents a major hurdle in the development of rational therapeutics for multiple sclerosis. Screening for remyelination is problematic, as myelination requires the presence of axons. Standard methods do not resolve cellautonomous effects and are not suited for high-throughput formats. Here we describe a binary indicant for myelination using micropillar arrays (BIMA). Engineered with conical dimensions, micropillars permit resolution of the extent and length of membrane wrapping from a single two-dimensional image. Confocal imaging acquired from the base to the tip of the pillars allows for detection of concentric wrapping observed as 'rings' of myelin. The platform is formatted in 96-well plates, amenable to semiautomated random acquisition and automated detection and quantification. Upon screening 1,000 bioactive molecules, we identified a cluster of antimuscarinic compounds that enhance oligodendrocyte differentiation and remyelination. Our findings demonstrate a new high-throughput screening platform for potential regenerative therapeutics in multiple sclerosis.
Functional screening for compounds that promote remyelination represents a major hurdle in the development of rational therapeutics for multiple sclerosis. Screening for remyelination is problematic, as myelination requires the presence of axons. Standard methods do not resolve cellautonomous effects and are not suited for high-throughput formats. Here we describe a binary indicant for myelination using micropillar arrays (BIMA). Engineered with conical dimensions, micropillars permit resolution of the extent and length of membrane wrapping from a single two-dimensional image. Confocal imaging acquired from the base to the tip of the pillars allows for detection of concentric wrapping observed as 'rings' of myelin. The platform is formatted in 96-well plates, amenable to semiautomated random acquisition and automated detection and quantification. Upon screening 1,000 bioactive molecules, we identified a cluster of antimuscarinic compounds that enhance oligodendrocyte differentiation and remyelination. Our findings demonstrate a new high-throughput screening platform for potential regenerative therapeutics in multiple sclerosis.
Loss of myelin in diseases such as multiple sclerosis results in the disruption of the nerve signal, damage to the axon and, finally, neurodegeneration. In order to effectively treat these devastating conditions, new methodologies and approaches to promote repair are required. Unlike many degenerative diseases of the central nervous system (CNS), the rationale for repair in multiple sclerosis is compelling and represents a realistic near-term goal. Remyelination occurs in multiple sclerosis, but it is limited to specific regions in the CNS and becomes less efficient over time, ultimately resulting in axonal degeneration, a chronic process that appears to underlie disability in the progressive forms of the disease 1 . In the adult brain, oligodendrocytes are terminally differentiated and generally do not participate in repair 2 . Rather, remyelination is mediated by oligodendrocyte precursor cells (OPCs), which are present throughout the CNS and are rapidly mobilized to demyelinated lesions [3] [4] [5] [6] . It is generally accepted that remyelination by adult OPCs is not hampered solely by issues of access or recruitment. Although adult OPCs may divide more slowly than their developmental counterparts [7] [8] [9] [10] , mitogens can augment proliferation of OPCs; however, they do not enhance remyelination in an aged mouse model 11 . This underscores the fact that a failure of OPC differentiation and membrane wrapping, rather than recruitment or migration of OPCs, is the critical barrier impeding myelin repair.
It has long been thought that the underlying mechanisms for oligodendrocyte differentiation and myelination are directly coupled to axonal signaling [12] [13] [14] [15] [16] . Recent findings have led to an alternative hypothesis suggesting that oligodendroglia have the capacity to myelinate paraformaldehyde-fixed axons 17 and even electron-spun nanofibers 18, 19 . These findings suggest that pseudoaxonal substrates are sufficient to initiate concentric wrapping by oligodendrocytes and provide a minimally permissive environment ideally suited for analyzing cell-autonomous mechanisms necessary and sufficient for modeling myelination. Although the nanofiber scaffold represents a major advance for screening compounds, the fibers are not suitable for high-throughput screening. Spinning and patterning the nanofibers reproducibly into microwells can be accomplished only with great difficulty and is extremely time consuming. Additionally, automated detection and quantification of myelin internodes is not currently feasible, as there are various confounding issues associated with the varying lengths of myelin internodes and spatially overlapping oligodendroglial processes and cell bodies. To date, there are no therapies for oligodendrocyte remyelination, and this fact alone illustrates a great unmet need in the development of methodologies and approaches for regeneration and repair. Functional screening for small bioactive molecules that promote oligodendrocyte survival, differentiation and remyelination represents a major hurdle to the identification and development of rational therapeutics. Technical advances in the development of high-throughput screening platforms are needed to clarify the cell-autonomous mechanisms responsible for differentiation and remyelination. In this Technical Report, we outline the criteria for and conception of a high-throughput screening platform for myelination, introduce the fabrication of micropillar arrays and present findings arising from the completion of a 1,000-compound library screen. We report the identification of a cluster of US Food and Drug Administration (FDA)-approved antimuscarinic compounds that greatly enhance oligodendrocyte differentiation and remyelination both in vitro and in vivo. Our findings and technical advances with new in vitro systems provide us with a unique opportunity to screen for and identify promising therapeutics for remyelination and repair in MS.
RESULTS

Fabrication of micropillar arrays for modeling myelination
We developed an approach that combines two innovative advances that together provide a platform for high-throughput screening, which we termed BIMA. We conceived the rationale for this approach after an in-depth examination of compressed z-stack images of oligodendrocytes wrapping nanofibers as previously described 18, 19 (Fig. 1a) . Upon examination of the side view of the myelin-like segments, we observed distinct myelin basic protein (MBP)-positive rings (Fig. 1b) . The rings represent a binary indicant for concentric membrane wrapping by oligodendrocytes. Therefore, we fabricated micropillar arrays of compressed silica into a 96-well format for a more efficient and rapid experimental design (Fig. 1c,d) . Essentially, micropillars represent freestanding nanofibers around which membrane wrapping can be visualized in cross-section, a feature that will allow for the detection of 'rings' of myelin membrane. Conceptually, as OPCs can also ensheathe nanofibers, imaging from the base to the tip of the pillars would allow for the quantification of rings made by OPCs and oligodendrocytes (Fig. 1e) . Additionally, we engineered the pillars in a conical shape, allowing for visualization and resolution of concentric membrane wrapping along the entire length of the pillar from a single two-dimensional image (Fig. 1f) . By measuring the dimensions of the MBP-positive membrane (base and tip diameter) from a compressed z-stack image, the length of the myelin-like segment can be interpolated from the dimensions of the pillar (Fig. 1d,f) . We designed and optimized each pillar with a larger base diameter (50 µm) that tapers to the tip (2 µm) and is 25 µm in height (Fig. 1d) . Essentially, individual pillars represent minimally permissive structures (length and diameter) that were previously determined by studies with nanofibers 18 . Each pillar is spaced at 50-µm intervals to allow for a reasonable number of oligodendroglia to adhere between the pillars (Fig. 1g) and to prevent membrane wrapping of multiple pillars from a single oligodendrocyte.
Oligodendrocytes cocultured with micropillars interacted with and ensheathed the pillars (Fig. 1g) . Whereas multiple OPCs interacted with single pillars, we observed by scanning electron microscopy (SEM) that oligodendrocytes typically paired with a single pillar (Fig. 1g) . After 5 d in culture, both OPCs (platelet-derived growth factor receptor-α (PDGFRα)-positive) and oligodendrocytes (MBPpositive) formed concentric rings around the pillars (Fig. 2a) . We acquired a 10-µm compressed z-stack image of an oligodendrocyte and neighboring OPC that clearly illustrates that the oligodendrocyte wraps the pillar concentrically, whereas the OPC only partially ensheathes the pillar with an incomplete ring (Fig. 2b) . This is consistent with previous findings illustrating ensheathment of nanofibers by OPCs and concentric wrapping by oligodendrocytes 18, 19 . In addition, the MBP-positive membrane surrounding the pillar is thicker than the PDGFRα-positive membrane, suggesting that the wrapping by oligodendrocytes spreads along the length of the pillar. npg view or from a 30°-tilted side-view image. Simple measurements of the base and tip diameters from the compressed z-stack image (Fig. 2c) permitted the resolution of the membrane extent and length of wrapping from a single two-dimensional image. Upon higher-magnification SEM imaging, we detected concentric membrane wrapping along the entire length of the pillar (Fig. 2d) and observed multiple layers of membrane near the tip of the pillar indicative of myelination (Fig. 2e) . This is consistent with the myelin-like segments previously identified along the nanofibers. Nevertheless, the concentric wrapping identified around the pillars demonstrates the utility of the micropillars as a scaffold for membrane wrapping that is detectable in a high-throughput assay.
High-throughput screening for differentiation and myelination
The flexibility in the design of micropillars guarantees consistent uniformity in the experimental design, and any effects from compounds tested can be attributed solely to direct influences on oligodendroglia without effects from neurons. Currently, the arrays are designed as 5.0-mm 2 -square chips bonded to the base of a 96-well bottomless plate. Approximately 10,000 micropillars are fabricated in each array, and 40,000 total OPCs are plated into each well. The number of OPCs were titrated and dispersed on to the micropillars to optimize for occupancy and reduce clustering of the cells. Additionally, the current density allows for analysis of effects on proliferation of OPCs and provides the sufficient range and space for detection.
The OPCs are seeded into the wells, allowed to settle and adhere for 48 h before the addition of screening compounds. Cells are cultured for 3 d with compounds at an initial concentration of 1 µM before fixation and immunostaining for MBP and PDGFRα. The 96-well plates are imaged on a motorized stage using a Zeiss LSM 700 confocal microscope and quantified by the Zen software. Upon initiating a screen of 1,000 bioactive molecules (Selleckchem), the effects of the compounds are quantified based on the average number of PDGFRα-and npg MBP-positive rings. These are acquired from four random 100-micropillar-containing fields from each individual array performed in triplicate. The data are plotted and grouped for proliferation and differentiation into four quadrants based on known positive control compounds (Fig. 3a) . On average, the control wells display approximately 50% OPC rings and 10% oligodendrocyte rings. This is represented at the intersection of the green and red lines that indicate the extent of the error bars associated with the control measurements. In our work, addition of PDGF, a potent mitogen for OPCs, resulted in an increase in the number of PDGFRα-positive rings and a concomitant decrease in MBP-positive rings (Fig. 3a) . This finding is consistent with the known role of PDGF as a mitogenic factor for OPCs that inhibits differentiation indirectly by promoting proliferation. As expected, addition of thyroid hormone (T3) and the tankyrase inhibitor XAV939 (ref. 20) , compounds that promote differentiation and myelination, resulted in an increase in the number of MBP-positive rings and depletion of PDGFRα-positive rings (Fig. 3a) . These findings are consistent with previously reported observations and validate the effectiveness of BIMA as a screening platform for oligodendrocyte differentiation and myelination.
Identification of antimuscarinic compounds
Upon completion of the screen, the majority of compounds tested were not found to have substantial effects on proliferation or differentiation of OPCs but instead caused a decrease in both PDGFRα-and MBP-positive rings. This finding suggests that multiple pathways and receptor ligands are necessary for OPC and oligodendrocyte survival and adhesion in vitro and that the decrease in oligodendroglial cells may be attributed to the toxicity of the limited concentrations of compounds tested (1 µM). In either case, future screening efforts and analysis of the compounds should reveal the direct or indirect effects on the decrease in the PDGFRα-and MBP-positive rings. Consistent with the fact that differentiation and proliferation are mutually exclusive processes, we identified clusters of compounds that promoted either proliferation or differentiation but not both (Fig. 3a) . In order to determine the effectiveness of our approach, we examined the cluster of compounds that were most potent in the generation of MBP-positive rings with a concomitant decrease in PDGFRα-positive rings. We identified a cluster of eight FDA-approved antimuscarinic compounds that significantly enhanced oligodendrocyte differentiation and membrane wrapping (Fig. 3f) . This cluster included the compounds atropine, ipratropium, oxybutynin, trospium, tiotropium, quetiapine, benzatropine and clemastine, also known as Tavist. Clemastine is a widely available first-generation antihistamine with a favorable safety profile for use. It is used primarily for symptomatic treatment of allergies and also exhibits antimuscarinic properties. We found that it greatly enhanced oligodendrocyte differentiation and wrapping (red rings) of micropillars, even when compared to the thyroid hormone T3 (Fig. 3b-f) . In order to validate the cluster of molecules identified by BIMA, we analyzed the effects of the individual compounds on purified OPCs cultured in isolation (Fig. 4a-e and Supplementary Fig. 1 ), as well as on OPCs cocultured with purified dorsal root ganglion (DRG) neurons 21 ( Fig. 4f-j) . Clemastine and benzatropine are FDA-approved compounds that cross the blood-brain barrier, and they were also the most effective in enhancing differentiation and myelination of oligodendrocytes (Fig. 4) . To determine whether clemastine and benzatropine represent effective candidates for remyelination, we examined the dose-response relationship between clemastine or benzatropine administration and OPC differentiation (Supplementary Fig. 1g ). Both compounds were most effective at 500 nM but promoted differentiation at as low as 10 nM. Consistent with findings from BIMA, the addition of clemastine, benzatropine or T3 significantly promoted differentiation and myelination without altering the number of oligodendroglial cells (Fig. 4f-j) . Although screening these compounds using BIMA clearly illustrates the differences in efficacy between clemastine, benzatropine and T3, the effects observed using cocultures were less notable. This observation is due to the fact that oligodendrocytes form elaborate overlapping processes and can form numerous myelin internodes in cocultures, saturating the range of detection of the MBP-positive signal and thereby decreasing the resolution for quantifying changes between compounds. As each oligodendrocyte is paired to a single micropillar, the dynamic range for the detection of MBP rings is far greater than that for OPCs and allows for a more robust and linear analysis when screening compounds. Notably, these findings identify a cluster of FDA-approved compounds with the potential to promote repair in multiple sclerosis. Additionally, the ability to quantify a functional readout for differentiation and membrane wrapping by oligodendrocytes represents a new opportunity to uncouple the contribution of active inductive cues on myelination from effects based on axon diameter alone.
Clemastine promotes remyelination in vivo
To determine whether clemastine represents an effective candidate for remyelination, we induced toxic injury in the white matter tracts of the spinal cord from adult mice and assessed the rate and extent of remyelination. We induced demyelination by injecting lysolecithin into the dorsal funiculus and ventrolateral white matter of adult mouse spinal cords (Fig. 5a ) 20, 22, 23 . Essential to this demyelinating model is the timeline for repair, comprising active demyelination 1-3 days post lesion (d.p.l.), OPC recruitment (3-7 (d.p.l.), peaking at 5 d.p.l.), oligodendrocyte differentiation (7-10 d.p.l.) and active remyelination (14-21 d.p.l.) 20, [22] [23] [24] . On the basis of our previous findings, we analyzed oligodendrocyte differentiation at 7 and 14 d.p.l. and remyelination at 14 d.p.l. by electron microscopy (Fig. 5) .
As clemastine has few adverse side effects, it represents a likely candidate for human remyelination trials. Therefore, we administered clemastine via oral gavage to adult mice at a concentration of 10 mg per kg body weight per day before initiating lysolecithin injections. plp in situ hybridization detected significantly more plp-positive oligodendrocytes in the lesion at 7 and 14 d.p.l. when compared to littermate controls (Fig. 5b,e) . In addition, both Cnp1 in situ hybridization (Fig. 5c ) and MBP immunostaining (Fig. 5d) of the lesions revealed enhanced differentiation of oligodendrocytes following the administration of clemastine at 14 d.p.l. Upon analysis of electron micrographs at 14 d.p.l., we found that the kinetics of remyelination were markedly accelerated in the lesions, with a corresponding decrease in the g-ratios ( Fig. 5f-h) , which represent myelin thickness with respect to axon size (ratio of axon diameter to the total fiber diameter). It is noteworthy that 29% of the axons detected were unmyelinated in the control lesions, whereas only 9% of the axons remained unmyelinated in the clemastine-treated mice (Fig. 5f) . These findings further support the conclusion that clemastine greatly promotes differentiation and accelerates the kinetics of remyelination after a demyelinating insult.
DISCUSSION
High-throughput screening for myelin repair is problematic, as compact wrapping of oligodendrocyte membrane requires the presence of neuronal axons. Although in vivo screening of compounds using larval zebrafish 25, 26 and in vitro screening using purified neuronaloligodendroglial cocultures 21 npg current methods do not resolve cell-autonomous and off-target effects, lack automated detection and quantification and are not well suited for high-throughput formats. Nevertheless, screenings with larval zebrafish and neuronal-oligodendroglial cocultures remain powerful tools that may be better suited for validation and secondary screening of compounds. Here we describe a binary indicant for myelination using micropillar arrays, which we named BIMA. Engineered with conical dimensions, micropillars permit resolution of the extent and length of membrane wrapping from a single two-dimensional image. The platform is currently formatted in 96-well plates and has also been designed to fit the 384-well plate format. Notably, the platform is not limited to screening in a minimally permissive environment but is also ideally suited to examine inhibitory components in the lesion environment. The micropillar arrays can be coated with various inhibitory substrates or membrane components and screened for compounds that overcome inhibition of differentiation and wrapping. Additionally, the micropillars are not limited to fixation of cells and immunostaining for OPC and oligodendrocyte markers but are highly adaptive to mouse oligodendroglia from fluorescence reporter mice and amenable to time-lapse imaging of differentiation and myelination ( Supplementary Fig. 2a-d) . Identical to the behavior of rat OPCs, mouse OPCs interact with micropillars and, upon differentiation into myelinating oligodendrocytes, can be visualized by a fluorescence reporter (Supplementary Fig. 2e) . Together, our results show that BIMA represents an unbiased approach for highthroughput screening of therapeutic compounds that can be adapted for continuous time-lapse imaging and may provide insight into new pathways and receptors essential for oligodendroglial development and myelination.
Upon completion of an initial screening of 1,000 bioactive molecules, we identified a cluster of eight FDA-approved compounds with antimuscarinic properties that enhanced oligodendrocyte differentiation and membrane wrapping. Included in this cluster is clemastine, a compound that exhibits both antimuscarinic and antihistaminic properties. The fact that five specific histamine receptor antagonists in the library do not display similar effects on oligodendroglia (data not shown) suggests that clemastine promotes oligodendrocyte differentiation and myelination via an off-target effect, namely, by blocking the muscarinic receptor. In line with this hypothesis, six muscarinic antagonists out of the cluster exhibited similar effects on oligodendroglia ( Supplementary Fig. 1b-d) . Previous reports confirm that muscarinic receptors are indeed expressed by oligodendroglial cells and may modulate OPC survival, proliferation and differentiation 27 . Clemastine represents the most effective compound among the cluster in promoting differentiation and myelination of oligodendroglia. Also, because clemastine penetrates the blood-brain barrier efficiently and has a favorable safety profile, it represents a promising candidate for multiple sclerosis therapy. We would be remiss if we did not mention that quetiapine, also known as Seroquel, is another FDA-approved compound that exhibits antimuscarinic properties and enhances oligodendrocyte differentiation and wrapping, albeit to a lesser extent than clemastine (Supplementary Fig. 1e,f) . Whether quetiapine promotes oligodendrocyte differentiation and myelination by blocking muscarinic receptors is currently undetermined, as the class of atypical antipsychotics is highly nonspecific and may act on numerous receptors and pathways. Nevertheless, our studies illustrate that oral treatment with quetiapine is effective in promoting remyelination after lysolecithin demyelination (Supplementary Fig. 3 ). Taken together, the identification of the cluster of antimuscarinic compounds in our screen illustrates the proof of concept for BIMA as a high-throughput screening platform that represents a path to potential drug discovery for multiple sclerosis. We are confident that expansion of the screen to include larger chemical libraries, including more FDA-approved compounds and unique bioactive molecules, will result in the identification and development of rational therapeutics for repair in multiple sclerosis.
METHODS
Methods and any associated references are available in the online version of the paper. 
